Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome

Clicks: 329
ID: 7990
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #7 of 32 articles by views in case reports in nephrology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
A 41-year-old woman developed nephrotic syndrome at the age of 32 and was diagnosed with minimal change nephrotic syndrome based on a renal biopsy. Although remission was achieved with administration of prednisolone (PSL) and cyclosporine, the nephrotic syndrome recurred. She was also started on rituximab (RTX). She developed late-onset neutropenia after RTX treatment (R-LON) and improved 17 days later. Although the majority of R-LON cases undergo spontaneous remission, cases of death have been reported. This report is intended to warn about R-LON, since the use of RTX for adult-onset nephrotic syndrome is expected to increase in the future.
Reference Key
mayuko2019lateonsetcase Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yamazaki, Mayuko;Sugiura, Hidekazu;Iwatani, Yosuke;Kyoda, Mizuki;Nokiba, Hirohiko;Amemiya, Nobuyuki;Nitta, Kosaku;Tsuchiya, Ken;Yamazaki, Mayuko;Sugiura, Hidekazu;Iwatani, Yosuke;Kyoda, Mizuki;Nokiba, Hirohiko;Amemiya, Nobuyuki;Nitta, Kosaku;Tsuchiya, Ken;
Journal case reports in nephrology
Year 2019
DOI
10.1155/2019/3580941
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.